Medtronic (NYSE:MDT) Releases FY 2027 Earnings Guidance

Medtronic (NYSE:MDT) updated its FY 2027 earnings guidance on Wednesday. The company provided earnings per share guidance of 5.900-6.000 for the period, compared to the consensus earnings per share estimate of 6.060. The company issued revenue guidance of -.

Analysts Set New Price Targets

A number of analysts recently issued reports on MDT shares. Wall Street Zen cut Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday, April 11th. Argus cut their price target on Medtronic from $125.00 to $115.00 and set a “buy” rating for the company in a research note on Monday, April 6th. Jefferies Financial Group reiterated a “hold” rating and set a $95.00 price target on shares of Medtronic in a report on Thursday, April 23rd. The Goldman Sachs Group set a $84.00 price target on Medtronic and gave the company a “neutral” rating in a research note on Thursday, May 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $120.00 price objective on shares of Medtronic in a research report on Thursday, March 26th. Fifteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $105.45.

Medtronic Stock Up 5.1%

Shares of NYSE MDT traded up $3.75 during mid-day trading on Wednesday, reaching $77.50. 8,063,995 shares of the company traded hands, compared to its average volume of 9,024,455. The company’s fifty day moving average is $82.11 and its two-hundred day moving average is $92.49. Medtronic has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The stock has a market cap of $99.50 billion, a PE ratio of 21.59, a price-to-earnings-growth ratio of 1.76 and a beta of 0.58.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.54 by $0.01. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company had revenue of $9.81 billion for the quarter, compared to the consensus estimate of $9.61 billion. During the same quarter last year, the company posted $1.62 earnings per share. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, analysts expect that Medtronic will post 5.54 earnings per share for the current year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were given a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.7%. Medtronic’s payout ratio is currently 79.11%.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic topped quarterly expectations with revenue of $9.81 billion and adjusted EPS of $1.55, helped by broad-based strength in cardiovascular, diabetes, and medical-surgical businesses. Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years
• Positive Sentiment: Cardiac Ablation Solutions was a standout, with revenue up 78% globally and 124% in the U.S., signaling strong demand in a key growth area. Medtronic beats quarterly estimates on robust demand for heart devices
• Positive Sentiment: Management issued upbeat FY2027 guidance for 6.75% to 7.25% organic revenue growth and non-GAAP EPS of $5.90 to $6.00, while also raising the quarterly dividend to $0.72 per share. Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years
• Positive Sentiment: The company also highlighted strategic investments and product expansion in robotic surgery and cardiac ablation, which may support longer-term growth. Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera technologies broadens
• Neutral Sentiment: Shares were also supported by commentary that investors looked past margin pressure and tariff headwinds because the top-line beat and guidance outweighed those concerns. Medtronic Stock Rises on Earnings. Wall Street Looks Past a Soft Outlook.
• Negative Sentiment: Margin pressure remains a headwind, and some coverage noted that FY2027 guidance was not strong enough to fully eliminate investor concern about costs and tariffs. Medtronic (MDT) Stock Surges on Q4 Beat Despite Tariff Headwinds and Weak FY27 Outlook

Institutional Trading of Medtronic

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MDT. Wellington Management Group LLP grew its stake in Medtronic by 35.3% in the third quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company’s stock valued at $970,456,000 after acquiring an additional 2,658,981 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Medtronic by 68.3% during the 3rd quarter. AQR Capital Management LLC now owns 3,329,414 shares of the medical technology company’s stock valued at $314,397,000 after purchasing an additional 1,350,888 shares in the last quarter. Lazard Asset Management LLC lifted its holdings in shares of Medtronic by 19.0% during the 3rd quarter. Lazard Asset Management LLC now owns 6,001,342 shares of the medical technology company’s stock valued at $571,502,000 after purchasing an additional 957,149 shares in the last quarter. Schroder Investment Management Group grew its position in shares of Medtronic by 12.5% in the 4th quarter. Schroder Investment Management Group now owns 8,468,982 shares of the medical technology company’s stock valued at $813,530,000 after purchasing an additional 939,133 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its stake in Medtronic by 62.6% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,430,723 shares of the medical technology company’s stock worth $231,502,000 after purchasing an additional 935,941 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).